Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes

Tonje H. Haukaas, Leslie R. Euceda, Guro F. Giske�deg�rd, Santosh Lamichhane, Marit Krohn, Sandra Jernstr�m, Miriam R. Aure, Ole C. Lingj�rde, Ellen Schlichting, �ystein Garred, Eldri U. Due, Gordon Mills, Kristine K. Sahlberg, Anne Lise B�rresen-Dale, Tone F. Bathen

Research output: Contribution to journalArticle

Abstract

Background: The heterogeneous biology of breast cancer leads to high diversity in prognosis and response to treatment, even for patients with similar clinical diagnosis, histology, and stage of disease. Identifying mechanisms contributing to this heterogeneity may reveal new cancer targets or clinically relevant subgroups for treatment stratification. In this study, we have merged metabolite, protein, and gene expression data from breast cancer patients to examine the heterogeneity at a molecular level. Methods: The study included primary tumor samples from 228 non-treated breast cancer patients. High-resolution magic-angle spinning magnetic resonance spectroscopy (HR MAS MRS) was performed to extract the tumors metabolic profiles further used for hierarchical cluster analysis resulting in three significantly different metabolic clusters (Mc1, Mc2, and Mc3). The clusters were further combined with gene and protein expression data. Results: Our result revealed distinct differences in the metabolic profile of the three metabolic clusters. Among the most interesting differences, Mc1 had the highest levels of glycerophosphocholine (GPC) and phosphocholine (PCho), Mc2 had the highest levels of glucose, and Mc3 had the highest levels of lactate and alanine. Integrated pathway analysis of metabolite and gene expression data uncovered differences in glycolysis/gluconeogenesis and glycerophospholipid metabolism between the clusters. All three clusters had significant differences in the distribution of protein subtypes classified by the expression of breast cancer-related proteins. Genes related to collagens and extracellular matrix were downregulated in Mc1 and consequently upregulated in Mc2 and Mc3, underpinning the differences in protein subtypes within the metabolic clusters. Genetic subtypes were evenly distributed among the three metabolic clusters and could therefore contribute to additional explanation of breast cancer heterogeneity. Conclusions: Three naturally occurring metabolic clusters of breast cancer were detected among primary tumors from non-treated breast cancer patients. The clusters expressed differences in breast cancer-related protein as well as genes related to extracellular matrix and metabolic pathways known to be aberrant in cancer. Analyses of metabolic activity combined with gene and protein expression provide new information about the heterogeneity of breast tumors and, importantly, the metabolic differences infer that the clusters may be susceptible to different metabolically targeted drugs.

Original languageEnglish (US)
Article number12
JournalCancer and Metabolism
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Breast Neoplasms
Gene Expression
Proteins
Metabolome
Neoplasms
Extracellular Matrix
Glycerophospholipids
Phosphorylcholine
Gluconeogenesis
Glycolysis
Metabolic Networks and Pathways
Alanine
Genes
Cluster Analysis
Lactic Acid
Histology
Magnetic Resonance Spectroscopy
Collagen
Down-Regulation
Glucose

Keywords

  • Breast cancer subgroups
  • Extracellular matrix
  • HR MAS MRS
  • Metabolic cluster
  • Metabolomics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism

Cite this

Haukaas, T. H., Euceda, L. R., Giske�deg�rd, G. F., Lamichhane, S., Krohn, M., Jernstr�m, S., ... Bathen, T. F. (2016). Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. Cancer and Metabolism, 4(1), [12]. https://doi.org/10.1186/s40170-016-0152-x

Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. / Haukaas, Tonje H.; Euceda, Leslie R.; Giske�deg�rd, Guro F.; Lamichhane, Santosh; Krohn, Marit; Jernstr�m, Sandra; Aure, Miriam R.; Lingj�rde, Ole C.; Schlichting, Ellen; Garred, �ystein; Due, Eldri U.; Mills, Gordon; Sahlberg, Kristine K.; B�rresen-Dale, Anne Lise; Bathen, Tone F.

In: Cancer and Metabolism, Vol. 4, No. 1, 12, 01.01.2016.

Research output: Contribution to journalArticle

Haukaas, TH, Euceda, LR, Giske�deg�rd, GF, Lamichhane, S, Krohn, M, Jernstr�m, S, Aure, MR, Lingj�rde, OC, Schlichting, E, Garred, Ï, Due, EU, Mills, G, Sahlberg, KK, B�rresen-Dale, AL & Bathen, TF 2016, 'Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes', Cancer and Metabolism, vol. 4, no. 1, 12. https://doi.org/10.1186/s40170-016-0152-x
Haukaas TH, Euceda LR, Giske�deg�rd GF, Lamichhane S, Krohn M, Jernstr�m S et al. Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. Cancer and Metabolism. 2016 Jan 1;4(1). 12. https://doi.org/10.1186/s40170-016-0152-x
Haukaas, Tonje H. ; Euceda, Leslie R. ; Giske�deg�rd, Guro F. ; Lamichhane, Santosh ; Krohn, Marit ; Jernstr�m, Sandra ; Aure, Miriam R. ; Lingj�rde, Ole C. ; Schlichting, Ellen ; Garred, �ystein ; Due, Eldri U. ; Mills, Gordon ; Sahlberg, Kristine K. ; B�rresen-Dale, Anne Lise ; Bathen, Tone F. / Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. In: Cancer and Metabolism. 2016 ; Vol. 4, No. 1.
@article{6874144539d8448c9410d4db2d7ca6e9,
title = "Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes",
abstract = "Background: The heterogeneous biology of breast cancer leads to high diversity in prognosis and response to treatment, even for patients with similar clinical diagnosis, histology, and stage of disease. Identifying mechanisms contributing to this heterogeneity may reveal new cancer targets or clinically relevant subgroups for treatment stratification. In this study, we have merged metabolite, protein, and gene expression data from breast cancer patients to examine the heterogeneity at a molecular level. Methods: The study included primary tumor samples from 228 non-treated breast cancer patients. High-resolution magic-angle spinning magnetic resonance spectroscopy (HR MAS MRS) was performed to extract the tumors metabolic profiles further used for hierarchical cluster analysis resulting in three significantly different metabolic clusters (Mc1, Mc2, and Mc3). The clusters were further combined with gene and protein expression data. Results: Our result revealed distinct differences in the metabolic profile of the three metabolic clusters. Among the most interesting differences, Mc1 had the highest levels of glycerophosphocholine (GPC) and phosphocholine (PCho), Mc2 had the highest levels of glucose, and Mc3 had the highest levels of lactate and alanine. Integrated pathway analysis of metabolite and gene expression data uncovered differences in glycolysis/gluconeogenesis and glycerophospholipid metabolism between the clusters. All three clusters had significant differences in the distribution of protein subtypes classified by the expression of breast cancer-related proteins. Genes related to collagens and extracellular matrix were downregulated in Mc1 and consequently upregulated in Mc2 and Mc3, underpinning the differences in protein subtypes within the metabolic clusters. Genetic subtypes were evenly distributed among the three metabolic clusters and could therefore contribute to additional explanation of breast cancer heterogeneity. Conclusions: Three naturally occurring metabolic clusters of breast cancer were detected among primary tumors from non-treated breast cancer patients. The clusters expressed differences in breast cancer-related protein as well as genes related to extracellular matrix and metabolic pathways known to be aberrant in cancer. Analyses of metabolic activity combined with gene and protein expression provide new information about the heterogeneity of breast tumors and, importantly, the metabolic differences infer that the clusters may be susceptible to different metabolically targeted drugs.",
keywords = "Breast cancer subgroups, Extracellular matrix, HR MAS MRS, Metabolic cluster, Metabolomics",
author = "Haukaas, {Tonje H.} and Euceda, {Leslie R.} and Giske{\"i}¿½deg{\"i}¿½rd, {Guro F.} and Santosh Lamichhane and Marit Krohn and Sandra Jernstr{\"i}¿½m and Aure, {Miriam R.} and Lingj{\"i}¿½rde, {Ole C.} and Ellen Schlichting and {\"i}¿½ystein Garred and Due, {Eldri U.} and Gordon Mills and Sahlberg, {Kristine K.} and B{\"i}¿½rresen-Dale, {Anne Lise} and Bathen, {Tone F.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1186/s40170-016-0152-x",
language = "English (US)",
volume = "4",
journal = "Cancer and Metabolism",
issn = "2049-3002",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes

AU - Haukaas, Tonje H.

AU - Euceda, Leslie R.

AU - Giske�deg�rd, Guro F.

AU - Lamichhane, Santosh

AU - Krohn, Marit

AU - Jernstr�m, Sandra

AU - Aure, Miriam R.

AU - Lingj�rde, Ole C.

AU - Schlichting, Ellen

AU - Garred, �ystein

AU - Due, Eldri U.

AU - Mills, Gordon

AU - Sahlberg, Kristine K.

AU - B�rresen-Dale, Anne Lise

AU - Bathen, Tone F.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: The heterogeneous biology of breast cancer leads to high diversity in prognosis and response to treatment, even for patients with similar clinical diagnosis, histology, and stage of disease. Identifying mechanisms contributing to this heterogeneity may reveal new cancer targets or clinically relevant subgroups for treatment stratification. In this study, we have merged metabolite, protein, and gene expression data from breast cancer patients to examine the heterogeneity at a molecular level. Methods: The study included primary tumor samples from 228 non-treated breast cancer patients. High-resolution magic-angle spinning magnetic resonance spectroscopy (HR MAS MRS) was performed to extract the tumors metabolic profiles further used for hierarchical cluster analysis resulting in three significantly different metabolic clusters (Mc1, Mc2, and Mc3). The clusters were further combined with gene and protein expression data. Results: Our result revealed distinct differences in the metabolic profile of the three metabolic clusters. Among the most interesting differences, Mc1 had the highest levels of glycerophosphocholine (GPC) and phosphocholine (PCho), Mc2 had the highest levels of glucose, and Mc3 had the highest levels of lactate and alanine. Integrated pathway analysis of metabolite and gene expression data uncovered differences in glycolysis/gluconeogenesis and glycerophospholipid metabolism between the clusters. All three clusters had significant differences in the distribution of protein subtypes classified by the expression of breast cancer-related proteins. Genes related to collagens and extracellular matrix were downregulated in Mc1 and consequently upregulated in Mc2 and Mc3, underpinning the differences in protein subtypes within the metabolic clusters. Genetic subtypes were evenly distributed among the three metabolic clusters and could therefore contribute to additional explanation of breast cancer heterogeneity. Conclusions: Three naturally occurring metabolic clusters of breast cancer were detected among primary tumors from non-treated breast cancer patients. The clusters expressed differences in breast cancer-related protein as well as genes related to extracellular matrix and metabolic pathways known to be aberrant in cancer. Analyses of metabolic activity combined with gene and protein expression provide new information about the heterogeneity of breast tumors and, importantly, the metabolic differences infer that the clusters may be susceptible to different metabolically targeted drugs.

AB - Background: The heterogeneous biology of breast cancer leads to high diversity in prognosis and response to treatment, even for patients with similar clinical diagnosis, histology, and stage of disease. Identifying mechanisms contributing to this heterogeneity may reveal new cancer targets or clinically relevant subgroups for treatment stratification. In this study, we have merged metabolite, protein, and gene expression data from breast cancer patients to examine the heterogeneity at a molecular level. Methods: The study included primary tumor samples from 228 non-treated breast cancer patients. High-resolution magic-angle spinning magnetic resonance spectroscopy (HR MAS MRS) was performed to extract the tumors metabolic profiles further used for hierarchical cluster analysis resulting in three significantly different metabolic clusters (Mc1, Mc2, and Mc3). The clusters were further combined with gene and protein expression data. Results: Our result revealed distinct differences in the metabolic profile of the three metabolic clusters. Among the most interesting differences, Mc1 had the highest levels of glycerophosphocholine (GPC) and phosphocholine (PCho), Mc2 had the highest levels of glucose, and Mc3 had the highest levels of lactate and alanine. Integrated pathway analysis of metabolite and gene expression data uncovered differences in glycolysis/gluconeogenesis and glycerophospholipid metabolism between the clusters. All three clusters had significant differences in the distribution of protein subtypes classified by the expression of breast cancer-related proteins. Genes related to collagens and extracellular matrix were downregulated in Mc1 and consequently upregulated in Mc2 and Mc3, underpinning the differences in protein subtypes within the metabolic clusters. Genetic subtypes were evenly distributed among the three metabolic clusters and could therefore contribute to additional explanation of breast cancer heterogeneity. Conclusions: Three naturally occurring metabolic clusters of breast cancer were detected among primary tumors from non-treated breast cancer patients. The clusters expressed differences in breast cancer-related protein as well as genes related to extracellular matrix and metabolic pathways known to be aberrant in cancer. Analyses of metabolic activity combined with gene and protein expression provide new information about the heterogeneity of breast tumors and, importantly, the metabolic differences infer that the clusters may be susceptible to different metabolically targeted drugs.

KW - Breast cancer subgroups

KW - Extracellular matrix

KW - HR MAS MRS

KW - Metabolic cluster

KW - Metabolomics

UR - http://www.scopus.com/inward/record.url?scp=85020920432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020920432&partnerID=8YFLogxK

U2 - 10.1186/s40170-016-0152-x

DO - 10.1186/s40170-016-0152-x

M3 - Article

VL - 4

JO - Cancer and Metabolism

JF - Cancer and Metabolism

SN - 2049-3002

IS - 1

M1 - 12

ER -